JP5753778B2 - 蠕虫卵、特に鞭虫卵の生物学的活性を測定する方法 - Google Patents
蠕虫卵、特に鞭虫卵の生物学的活性を測定する方法 Download PDFInfo
- Publication number
- JP5753778B2 JP5753778B2 JP2011509973A JP2011509973A JP5753778B2 JP 5753778 B2 JP5753778 B2 JP 5753778B2 JP 2011509973 A JP2011509973 A JP 2011509973A JP 2011509973 A JP2011509973 A JP 2011509973A JP 5753778 B2 JP5753778 B2 JP 5753778B2
- Authority
- JP
- Japan
- Prior art keywords
- eggs
- larvae
- measurement
- trichinella
- encapsulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 235000013601 eggs Nutrition 0.000 title claims description 210
- 238000000034 method Methods 0.000 title claims description 96
- 230000004071 biological effect Effects 0.000 title claims description 45
- 241000243774 Trichinella Species 0.000 title claims description 18
- 244000000013 helminth Species 0.000 title description 37
- 108010034145 Helminth Proteins Proteins 0.000 title description 36
- 238000005259 measurement Methods 0.000 claims description 66
- 238000012360 testing method Methods 0.000 claims description 55
- 230000004899 motility Effects 0.000 claims description 48
- 239000000523 sample Substances 0.000 claims description 29
- 238000004458 analytical method Methods 0.000 claims description 26
- 230000012447 hatching Effects 0.000 claims description 25
- 238000010171 animal model Methods 0.000 claims description 23
- 230000014509 gene expression Effects 0.000 claims description 21
- 241001465754 Metazoa Species 0.000 claims description 20
- 241001489151 Trichuris Species 0.000 claims description 20
- 230000001418 larval effect Effects 0.000 claims description 20
- 238000011533 pre-incubation Methods 0.000 claims description 12
- 238000003753 real-time PCR Methods 0.000 claims description 12
- 230000002503 metabolic effect Effects 0.000 claims description 11
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 10
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 10
- 239000007850 fluorescent dye Substances 0.000 claims description 9
- 210000003608 fece Anatomy 0.000 claims description 7
- 238000004020 luminiscence type Methods 0.000 claims description 7
- 238000011002 quantification Methods 0.000 claims description 6
- 230000007653 larval development Effects 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 238000000684 flow cytometry Methods 0.000 claims description 4
- 230000007774 longterm Effects 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 102000012286 Chitinases Human genes 0.000 claims description 2
- 108010022172 Chitinases Proteins 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
- 238000010170 biological method Methods 0.000 claims description 2
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 238000009396 hybridization Methods 0.000 claims 2
- 238000002306 biochemical method Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000012790 confirmation Methods 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 description 35
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 33
- 208000015181 infectious disease Diseases 0.000 description 29
- 230000000694 effects Effects 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 26
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 22
- 230000004913 activation Effects 0.000 description 22
- 238000000338 in vitro Methods 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 241000282887 Suidae Species 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- 210000003736 gastrointestinal content Anatomy 0.000 description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 description 9
- 230000002779 inactivation Effects 0.000 description 9
- 108060001084 Luciferase Proteins 0.000 description 8
- 238000007710 freezing Methods 0.000 description 8
- 230000008014 freezing Effects 0.000 description 8
- 239000005089 Luciferase Substances 0.000 description 7
- 238000000691 measurement method Methods 0.000 description 7
- 210000001082 somatic cell Anatomy 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- 238000011088 calibration curve Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 241001465677 Ancylostomatoidea Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000000877 morphologic effect Effects 0.000 description 5
- 241000244203 Caenorhabditis elegans Species 0.000 description 4
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 4
- 101150031823 HSP70 gene Proteins 0.000 description 4
- -1 adenosine triphosphates Chemical class 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 101150052825 dnaK gene Proteins 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000007901 in situ hybridization Methods 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 208000030852 Parasitic disease Diseases 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 235000013405 beer Nutrition 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000007447 staining method Methods 0.000 description 3
- 241000254173 Coleoptera Species 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241001439624 Trichina Species 0.000 description 2
- 241000960389 Trichuris suis Species 0.000 description 2
- 241001489145 Trichuris trichiura Species 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 210000003278 egg shell Anatomy 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- ZQDAIIUFJKGWON-LBPRGKRZSA-N 5-[(2s)-2-(pyridin-3-yloxymethyl)pyrrolidin-1-yl]sulfonyl-1h-indole-2,3-dione Chemical group C([C@@H]1CCCN1S(=O)(=O)C1=CC=C2NC(C(C2=C1)=O)=O)OC1=CC=CN=C1 ZQDAIIUFJKGWON-LBPRGKRZSA-N 0.000 description 1
- 238000002970 ATP quantitation Methods 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000006968 Helminthiasis Diseases 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 108091023242 Internal transcribed spacer Proteins 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000254064 Photinus pyralis Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010044608 Trichiniasis Diseases 0.000 description 1
- 241001221734 Trichuris muris Species 0.000 description 1
- 241001638368 Trichuris vulpis Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- LIYGYAHYXQDGEP-UHFFFAOYSA-N firefly oxyluciferin Natural products Oc1csc(n1)-c1nc2ccc(O)cc2s1 LIYGYAHYXQDGEP-UHFFFAOYSA-N 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000010359 gene isolation Methods 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- JJVOROULKOMTKG-UHFFFAOYSA-N oxidized Photinus luciferin Chemical compound S1C2=CC(O)=CC=C2N=C1C1=NC(=O)CS1 JJVOROULKOMTKG-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 208000009920 trichuriasis Diseases 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
- G01N2333/43526—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08009344.6 | 2008-05-21 | ||
| EP08009344A EP2123774A1 (de) | 2008-05-21 | 2008-05-21 | Verfahren zur Charakterisierung der biologischen Aktivität von Helminth-Eiern |
| PCT/EP2009/056106 WO2009156232A1 (de) | 2008-05-21 | 2009-05-20 | Verfahren zur charakterisierung der biologischen aktivität von helminth-eiern, nämlich von trichuris eiern |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011523847A JP2011523847A (ja) | 2011-08-25 |
| JP2011523847A5 JP2011523847A5 (https=) | 2012-04-12 |
| JP5753778B2 true JP5753778B2 (ja) | 2015-07-22 |
Family
ID=39768691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011509973A Expired - Fee Related JP5753778B2 (ja) | 2008-05-21 | 2009-05-20 | 蠕虫卵、特に鞭虫卵の生物学的活性を測定する方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8993332B2 (https=) |
| EP (2) | EP2123774A1 (https=) |
| JP (1) | JP5753778B2 (https=) |
| CN (1) | CN102037141B (https=) |
| AU (1) | AU2009262381B2 (https=) |
| CA (1) | CA2723402C (https=) |
| CY (1) | CY1116916T1 (https=) |
| DK (1) | DK2279264T3 (https=) |
| ES (1) | ES2552356T3 (https=) |
| HR (1) | HRP20151173T1 (https=) |
| HU (1) | HUE026151T2 (https=) |
| PL (1) | PL2279264T3 (https=) |
| PT (1) | PT2279264E (https=) |
| RU (1) | RU2540145C2 (https=) |
| SI (1) | SI2279264T1 (https=) |
| UA (1) | UA103769C2 (https=) |
| WO (1) | WO2009156232A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2492637C2 (ru) * | 2011-07-26 | 2013-09-20 | Закрытое акционерное общество "АЛЬФА-ТЭК" | Способ предынкубационной обработки яиц препаратом галосепт |
| US9224200B2 (en) | 2012-04-27 | 2015-12-29 | Parasite Technologies A/S | Computer vision based method for extracting features relating to the developmental stages of Trichuris spp. eggs |
| RU2609145C2 (ru) * | 2015-06-08 | 2017-01-30 | ФАНО России Федеральное государственное бюджетное научное учреждение Всероссийский научно-исследовательский институт фундаментальной и прикладной паразитологии животных и растений им. К.И. Скрябина (ФГБНУ "ВНИИП им. К.И. Скрябина") | Способ сбора максимального количества зрелых (=оплодотворённых) яиц (in vitro) от самок возбудителя паразитарного зооноза trichuris (=trichocephalus) suis |
| US9603875B1 (en) | 2016-01-07 | 2017-03-28 | NeuOva, LLC | Method of making a consumable product with purified embryonated Trichuris suis ova |
| JP6231709B1 (ja) | 2016-05-31 | 2017-11-15 | シスメックス株式会社 | 蛍光画像分析装置および分析方法 |
| CN106689063B (zh) * | 2016-12-07 | 2020-03-17 | 中国科学院动物研究所 | 一种稻螟赤眼蜂的人工繁育生产方法 |
| WO2025259635A1 (en) * | 2024-06-10 | 2025-12-18 | Parasight System Inc. | Methods for analyzing fecal matter using fluorochromes that covalently bond to parasitic material |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2315790C (en) | 1997-12-31 | 2015-10-06 | University Of Iowa Research Foundation | Use of parasitic biological agents for prevention and control of autoimmune diseases |
| US7083911B2 (en) | 2001-02-16 | 2006-08-01 | Promega Corporation | Method for detection of ATP |
| EP1968618B1 (en) * | 2005-12-30 | 2017-05-10 | Parasite Technologies A/S | Composition comprising parasite eggs and methods for isolation and storage of parasite eggs |
| DE102006023906A1 (de) | 2006-05-19 | 2007-11-22 | Ovamed Gmbh | Verfahren zum Nachweis der Viabilität |
-
2008
- 2008-05-21 EP EP08009344A patent/EP2123774A1/de not_active Withdrawn
-
2009
- 2009-05-20 RU RU2010152016/10A patent/RU2540145C2/ru not_active IP Right Cessation
- 2009-05-20 ES ES09769081.2T patent/ES2552356T3/es active Active
- 2009-05-20 CN CN200980118522.9A patent/CN102037141B/zh not_active Expired - Fee Related
- 2009-05-20 US US12/993,517 patent/US8993332B2/en not_active Expired - Fee Related
- 2009-05-20 DK DK09769081.2T patent/DK2279264T3/en active
- 2009-05-20 CA CA2723402A patent/CA2723402C/en not_active Expired - Fee Related
- 2009-05-20 PL PL09769081T patent/PL2279264T3/pl unknown
- 2009-05-20 HR HRP20151173TT patent/HRP20151173T1/hr unknown
- 2009-05-20 SI SI200931292T patent/SI2279264T1/sl unknown
- 2009-05-20 HU HUE09769081A patent/HUE026151T2/en unknown
- 2009-05-20 AU AU2009262381A patent/AU2009262381B2/en not_active Ceased
- 2009-05-20 UA UAA201015255A patent/UA103769C2/ru unknown
- 2009-05-20 JP JP2011509973A patent/JP5753778B2/ja not_active Expired - Fee Related
- 2009-05-20 WO PCT/EP2009/056106 patent/WO2009156232A1/de not_active Ceased
- 2009-05-20 PT PT97690812T patent/PT2279264E/pt unknown
- 2009-05-20 EP EP09769081.2A patent/EP2279264B1/de active Active
-
2015
- 2015-11-13 CY CY20151101026T patent/CY1116916T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1116916T1 (el) | 2017-04-05 |
| WO2009156232A1 (de) | 2009-12-30 |
| JP2011523847A (ja) | 2011-08-25 |
| RU2010152016A (ru) | 2012-06-27 |
| PL2279264T3 (pl) | 2016-01-29 |
| SI2279264T1 (sl) | 2015-11-30 |
| RU2540145C2 (ru) | 2015-02-10 |
| CN102037141A (zh) | 2011-04-27 |
| EP2279264B1 (de) | 2015-08-19 |
| US8993332B2 (en) | 2015-03-31 |
| UA103769C2 (ru) | 2013-11-25 |
| HRP20151173T1 (hr) | 2015-12-04 |
| EP2279264A1 (de) | 2011-02-02 |
| ES2552356T3 (es) | 2015-11-27 |
| DK2279264T3 (en) | 2015-11-23 |
| AU2009262381A1 (en) | 2009-12-30 |
| AU2009262381B2 (en) | 2015-03-26 |
| US20110191869A1 (en) | 2011-08-04 |
| EP2123774A1 (de) | 2009-11-25 |
| HK1147113A1 (en) | 2011-07-29 |
| US20120060229A9 (en) | 2012-03-08 |
| PT2279264E (pt) | 2015-11-20 |
| WO2009156232A9 (de) | 2010-02-18 |
| CA2723402C (en) | 2018-06-19 |
| CN102037141B (zh) | 2014-02-26 |
| CA2723402A1 (en) | 2009-12-30 |
| HUE026151T2 (en) | 2016-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5753778B2 (ja) | 蠕虫卵、特に鞭虫卵の生物学的活性を測定する方法 | |
| US10031080B2 (en) | Method for recognizing resistant germs and device for performing same | |
| JP2011523847A5 (https=) | ||
| Liyanage et al. | Molecular detection and characterisation of Toxoplasma gondii in eastern barred bandicoots (Perameles gunnii) in Victoria, Australia | |
| Kwon et al. | Visualizing biofilm by targeting eDNA with long wavelength probe CDr15 | |
| KR101863458B1 (ko) | 리얼타임 pcr을 이용한 살모넬라 감염증 원인균 검사 키트 및 방법 | |
| US20240117404A1 (en) | Automatic Phagogram | |
| Wang et al. | Establishment of a method for detecting Trichinella spiralis in ovine muscle tissues using real-time fluorescence quantitative PCR | |
| EP1529117A2 (en) | Method for the rapid assessment of the presence and viability of bacterial cells and use thereof | |
| RU2839982C1 (ru) | Способ выявления РНК вируса Mammarenavirus guanaritoense методом ОТ-ПЦР в реальном времени | |
| RU2489489C1 (ru) | Способ определения бактерицидных свойств сыворотки крови | |
| RU2816270C2 (ru) | Способ выявления вируса Nipah методом ОТ-ПЦР в реальном времени | |
| RU2759232C1 (ru) | Способ оценки эффективности терапии лепры с использованием полимеразной цепной реакции для амплификации видоспецифичных участков геномов лепры, человека или мыши | |
| HK1147113B (en) | Method for characterising the biological activity of trichuris eggs | |
| CN113801191B (zh) | 一种检测衣原体的多肽探针及其应用 | |
| Nurlygayanova et al. | Diagnoses of Leptospirosis in Animals | |
| SuLI et al. | Comparison of Conventional and Molecular Diagnostic Techniques for Detection of Blastocystis sp. in Pig Faeces | |
| Niemeyer | May the worm story begin… Evaluation of Caenorhabditis elegans as model for investigations into bacterial cross talk during intestinal immune responses | |
| Klangnurak | Candidate gene identification of ovulation-inducing genes with in vivo assay in zebrafish | |
| CZ33436U1 (cs) | Sada oligonukleotidových sekvencí a rekombinantní plazmid pro detekci bakterií druhu Paenibacillus larvae | |
| Bauer | Investigation into the pathogenesis of retinal dysplasia in the miniature schnauzer and English springer spaniel dog | |
| Eickhoff | Chlamydiaceae and Chronic Diseases: Clinical Implications and Host-Cell Gene Expression in a Model of Interferon-gamma-Induced Persistence | |
| Menéndez | Characterization Of Human Models In Drosophila melanogaster For The Study Of Spastic Paraplegia Type 7 | |
| CN104946768A (zh) | 检测牛LF基因mRNA表达水平的特异性引物和荧光定量检测试剂盒 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110316 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110317 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120224 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120224 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131008 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131219 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131227 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140123 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140130 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140221 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140228 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140404 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141028 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150116 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150507 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150525 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5753778 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |